CaulophineCAS# 1159989-19-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1159989-19-1 | SDF | Download SDF |
| PubChem ID | 70680258 | Appearance | Powder |
| Formula | C19H21NO5 | M.Wt | 343.37 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-[2-(dimethylamino)ethyl]-4,5-dihydroxy-1,6-dimethoxyfluoren-9-one | ||
| SMILES | CN(C)CCC1=CC(=C2C(=C1O)C3=C(C2=O)C=CC(=C3O)OC)OC | ||
| Standard InChIKey | NDCDKMMCPZJBEB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H21NO5/c1-20(2)8-7-10-9-13(25-4)15-16(17(10)21)14-11(18(15)22)5-6-12(24-3)19(14)23/h5-6,9,21,23H,7-8H2,1-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Caulophine has the ability to protect cardiomyocytes from oxidative and ischemic injury through an antioxidative mechanism. |
| Targets | SOD |
Caulophine Dilution Calculator
Caulophine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9123 mL | 14.5616 mL | 29.1231 mL | 58.2462 mL | 72.8078 mL |
| 5 mM | 0.5825 mL | 2.9123 mL | 5.8246 mL | 11.6492 mL | 14.5616 mL |
| 10 mM | 0.2912 mL | 1.4562 mL | 2.9123 mL | 5.8246 mL | 7.2808 mL |
| 50 mM | 0.0582 mL | 0.2912 mL | 0.5825 mL | 1.1649 mL | 1.4562 mL |
| 100 mM | 0.0291 mL | 0.1456 mL | 0.2912 mL | 0.5825 mL | 0.7281 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Abiesadine N
Catalog No.:BCN6041
CAS No.:1159913-80-0
- CZC24832
Catalog No.:BCC1507
CAS No.:1159824-67-5
- Poricoic acid AE
Catalog No.:BCN7282
CAS No.:1159753-88-4
- Alstonic acid B
Catalog No.:BCN6040
CAS No.:1159579-45-9
- Alstonic acid A
Catalog No.:BCN6039
CAS No.:1159579-44-8
- Salvianolic acid B
Catalog No.:BCN6106
CAS No.:115939-25-8
- Tarafenacin D-tartrate
Catalog No.:BCC4148
CAS No.:1159101-48-0
- Angoroside C
Catalog No.:BCN4997
CAS No.:115909-22-3
- Tos-Arg-OH
Catalog No.:BCC2873
CAS No.:1159-15-5
- N1-Methoxymethyl picrinine
Catalog No.:BCN6038
CAS No.:1158845-78-3
- Aurora A Inhibitor I
Catalog No.:BCC2182
CAS No.:1158838-45-9
- Salvianolic acid C
Catalog No.:BCN5376
CAS No.:115841-09-3
- TC-I 2000
Catalog No.:BCC6244
CAS No.:1159996-20-9
- Aldicarb
Catalog No.:BCC5475
CAS No.:116-06-3
- 4-Amino-3-hydroxy-1-naphthalenesulfonic acid
Catalog No.:BCC8680
CAS No.:116-63-2
- 1-Amino-4-hydroxyanthraquinone
Catalog No.:BCC8452
CAS No.:116-85-8
- VU 0238429
Catalog No.:BCC7729
CAS No.:1160247-92-6
- MLN4924 HCl salt
Catalog No.:BCC1773
CAS No.:1160295-21-5
- Pyr3
Catalog No.:BCC7771
CAS No.:1160514-60-2
- Piperolactam C
Catalog No.:BCN4818
CAS No.:116064-76-7
- Dehydromiltirone
Catalog No.:BCN5357
CAS No.:116064-77-8
- IDE 1
Catalog No.:BCC7841
CAS No.:1160927-48-9
- RETF-4NA
Catalog No.:BCC6073
CAS No.:1160928-63-1
- Z-Phe-OH
Catalog No.:BCC2756
CAS No.:1161-13-3
Caulophine protects cardiomyocytes from oxidative and ischemic injury.[Pubmed:20724803]
J Pharmacol Sci. 2010;113(4):368-77.
Caulophine is a new fluorenone alkaloid isolated from the radix of Caulophyllum robustum MAXIM and identified as 3-(2-(dimethylamino) ethyl)-4,5-dihydroxy-1,6-dimethoxy-9H-fluoren-9-one. Due to its new chemical structure, the pharmacological activities of Caulophine are not well characterized. The present study evaluated the protective effect and the primary mechanisms of Caulophine on cardiomyocyte injury. Viability of cardiomyocytes was assayed with the MTT method, and cell apoptosis was detected by flow cytometry. Myocardial infarction was produced by ligating the coronary artery, and myocardial ischemia was induced by isoproterenol in rats. Myocardial infarction size was estimated with p-nitro-blue tetrazolium staining. Lactate dehydrogenase (LDH), creatine kinase (CK), superoxide dismutase (SOD), malondialdehyde (MDA), and free fatty acid (FFA) were spectrophotometrically determined. Histopathological and ultrastructural changes of ischemic myocardium were observed. The results showed that pretreatment with Caulophine increased the viability of H(2)O(2)- and adriamycin-injured cardiomyocytes; decreased CK, LDH, and MDA; increased SOD; and inhibited H(2)O(2)-induced cellular apoptosis. Caulophine reduced myocardial infarct size and serum CK, LDH, FFA, and MDA; raised serum SOD; and improved histopathological and ultrastructural changes of ischemic myocardium. The results demonstrate that Caulophine has the ability to protect cardiomyocytes from oxidative and ischemic injury through an antioxidative mechanism that provides a basis for further study and development of Caulophine as a promising agent for treating coronary heart disease.
Fluorenone alkaloid from Caulophyllum robustum Maxim. with anti-myocardial ischemia activity.[Pubmed:19407969]
Arch Pharm Res. 2009 Apr;32(4):521-6.
A new fluorenone alkaloid (Caulophine) was isolated from the radix of Caulophyllum robustum Maxim. (collected from the Qinling mountains) using cell membrane chromatography as the screening method. Caulophine was identified as 3-(2-(dimethylamino)ethyl)-4,5-dihydroxy-1,6-dimethoxy-9H-fluoren-9-one based on physicochemic and spectroscopic analyses, particularly by NMR spectroscopic data (i.e., COSY, HMQC, HMBC, NOESY). Caulophine possessed anti-myocardial ischemia activity.
